Santhera

Duchenne muscular dystrophy: major trials and events to watch in 2023
Duchenne muscular dystrophy: major trials and events to watch in 2023
Clinical Trials Arena
DMD
Duchenne Muscular Dystrophy
clinical trials
gene therapy
FDA
Sarepta Therapeutics
SRP-9001
FibroGen
pamrevlumab
Capricor
CAP-1002
Santhera
ReveraGen
vamorolone
Flag link:
Santhera seeks speedy FDA review of Duchenne drug vamorolone
Santhera seeks speedy FDA review of Duchenne drug vamorolone
Pharmaphorum
Santhera
Duchenne Muscular Dystrophy
vamorolone
FDA
Flag link:
Buoyed by new data, Santhera preps filing for DMD drug vamorolone
Buoyed by new data, Santhera preps filing for DMD drug vamorolone
Pharmaforum
Santhera
DMD
Duchenne Muscular Dystrophy
idebenone
vamorolone
FDA
Flag link:
Second-quarter catalysts for the smaller players
Second-quarter catalysts for the smaller players
EP Vantage
AC Immune
Anavex
Santhera
IMMUTEP
Syndax
Novan
Fulcrum Therapeutics
BeyondSpring
Corbus
Orphazyme
Aldeyra
Adaptimmune
Inflarx
Sutro
Gemini Therapeutics
Flag link:
Three Biotechs Shutter Clinical Programs After Futility Analysis or Failed Trials
Three Biotechs Shutter Clinical Programs After Futility Analysis or Failed Trials
BioSpace
Jounce Therapeutics
vopratelimab
Santhera
vamorolone
Puldysa
Aurinia Pharmaceuticals
FOS
Flag link:
Santhera axes half its employees and sees CMO depart after PhIII DMD fail
Santhera axes half its employees and sees CMO depart after PhIII DMD fail
Endpoints
Santhera
reorganization
Duchenne Muscular Dystrophy
vamorolone
layoffs
Flag link:
Santhera bags DMD drug in 3-way deal with Idorsia and ReveraGen
Santhera bags DMD drug in 3-way deal with Idorsia and ReveraGen
Fierce Biotech
Santhera
vamorolone
Duchenne Muscular Dystrophy
Idorsia
ReveraGen
Flag link:
Santhera's Duchenne effort gets a boost on positive PhIIa for alternative steroid vamorolone — though there's a lot left to prove
Santhera's Duchenne effort gets a boost on positive PhIIa for alternative steroid vamorolone — though there's a lot left to prove
Endpoints
Santhera
Duchenne Muscular Dystrophy
clinical trials
vamorolone
RaveraGen
Flag link:
Early access to Santhera’s DMD therapy Raxone extended in the UK
Early access to Santhera’s DMD therapy Raxone extended in the UK
Pharma Times
UK
Santhera
Raxone
Duchenne Muscular Dystrophy
Flag link:
How the newest Duchenne biotechs are getting a boost from patient groups
How the newest Duchenne biotechs are getting a boost from patient groups
Bizjournals.com
patients
patient groups
Duchenne Muscular Dystrophy
Sarepta Therapeutics
Santhera
Catabasis
Akashi Therapeutics
Summit Therapeutics
Solid Biosciences
Flag link:
Sarepta Stock Slides As FDA Sends Another Bad Signal On DMD
Sarepta Stock Slides As FDA Sends Another Bad Signal On DMD
Investors.com
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
Raxone
Kyndrisa
Santhera
Flag link:
Duchenne Drug Developer (Not Sarepta) Hit with Lengthy FDA Delay
Duchenne Drug Developer (Not Sarepta) Hit with Lengthy FDA Delay
TheStreet.com
Raxone
Duchenne Muscular Dystrophy
Santhera
Flag link:
Santhera May Market Muscular Dystrophy Drug on its Own in U.S.
Santhera May Market Muscular Dystrophy Drug on its Own in U.S.
Bloomberg
Santhera
Duchenne Muscular Dystrophy
Catena
Flag link:
Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015
Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015
TheStreet.com
Sanofi
MannKind
Gilead Sciences
Santhera
Puma Biotechnology
Bluebird Bio
Celgene
Pfizer
Biogen Idec
Flag link:
InVivo's Pharma Deals of the Week
InVivo's Pharma Deals of the Week
InVivo
Biovail
Santhera
Warner Chilcott
Proctor & Gamble
Ligand
Neurogen
Shire
Santaris
Flag link:
Biovail to develop Parkinson Drug
Biovail to develop Parkinson Drug
Yahoo/Zacks.com
Biovail
Parkinson's Disease
Santhera
Flag link: